Work

Phase 1 trial of pegzilarginase in patients (pts) with relapsed/refractory (R/R) AML or MDS refractory to hypomethylating agents (HMAs).

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.7031

Authors: Geoffrey L. Uy, Michael R. Savona, Benjamin K. Tomlinson, Hetty Carraway, Dale L. Bixby, Sarit E. Assouline, Joseph M. Brandwein, Moshe Yair Levy, Robert Collins, Humberto Lara-Guerra, Susan Alters, Stephen Eckert, Scott Rowlinson, James Wooldridge, Aaron David Schimmer

Institutions: Washington University in St. Louis, Vanderbilt University Medical Center, University Hospitals Cleveland Medical Center, University Hospitals Seidman Cancer Center, Cleveland Clinic, University of Michigan, Jewish General Hospital, University of Alberta, The University of Texas Southwestern Medical Center, University Health Network, Princess Margaret Cancer Centre

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2889569424

Cites:

Cited by: 2

Related to: 10